© Reuters. FILE PHOTO: GSK (GlaxoSmithKline) brand is seen on this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Picture
LONDON (Reuters) – GSK mentioned on Thursday it had accomplished the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical firm targeted on respiratory and inflammatory circumstances.
GSK can pay $1 billion upfront and as much as $400 million in success-based milestone funds.
“As well as, GSK may also be chargeable for success-based milestone funds in addition to tiered royalties owed to Jiangsu Hengrui Prescribed drugs Co, Ltd,” the group mentioned.